CD19 and diffuse large B-cell lymphoma: Lisocabtagene maraleucel is available commercially as liso-cel or Breyanzi and is a CD19-directed CAR-T-cell therapy that received its approval by the FDA on 5 January 2021 for the treatment of large B-cell lymphoma in adult patients post-systemic therapy (two or more lines), HGBCL, DLBCL, primary mediastinal large B-cell lymphoma, and grade 3b follicular lymphoma patients [128].